Shoulder Innovations Initiates Full Commercial Launch of the InSet™ I-135RFX Humeral Stem

Shoulder Innovations (NYSE: SI) announced the full commercial launch of the InSet™ I-135RFX humeral stem on April 27, 2026.

Rhea-AI Summary

Shoulder Innovations (NYSE: SI) announced the full commercial launch of the InSet™ I-135RFX humeral stem on April 27, 2026. The launch follows a limited market release and additional FDA 510(k) clearance expanding fracture indications, enabling use in primary, revision, and fracture total shoulder arthroplasty.

The I-135RFX is the third InSet humeral stem in three years and uses the company’s InSet lateral-lateral implant philosophy, which independent peer-reviewed research has associated with fewer complications and improved post-operative range of motion.

Positive

• FDA 510(k) clearance for expanded fracture indications
• Full commercial launch for primary, revision, and fracture procedures
• Third InSet humeral stem added within three years
• Built on InSet lateral-lateral philosophy linked to peer-reviewed research
• Surgeon-reported ease of use and integration with two-tray instrumentation

Negative

• None.

Argus Apr 27 session

+4.32% close to close Open Argus

Details

News Market Reaction – SI

On Apr 27, the day this news came out, SI closed 4.32% above the previous close.

Data tracked by StockTitan Argus for the Apr 27 session.

Market Context

This announcement extends Shoulder Innovations’ I-Series humeral stem portfolio, with the InSet I-13...

Analysis

This announcement extends Shoulder Innovations’ I-Series humeral stem portfolio, with the InSet I-135RFX now cleared via FDA 510(k) for primary, revision, and fracture total shoulder arthroplasty. It follows earlier InSet 95 and 70 launches, reinforcing the company’s focus on comprehensive shoulder solutions. In context of strong recent revenue growth but ongoing losses, investors may watch adoption trends for this stem, surgeon feedback, and how it contributes to future earnings updates and regulatory disclosures.

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   Earnings date notice

   24h Move

   -4.5%

   Announcement of timing for Q1 2026 results and conference call logistics.

2. Mar 10

   Earnings results

   24h Move

   +7.4%

   Strong Q4 and 2025 revenue growth with high gross margins and raised guidance.

3. Mar 02

   Board change

   24h Move

   -0.2%

   Appointment of experienced medtech executive Drew Hykes to Board and committees.

4. Feb 18

   Conference participation

   24h Move

   +2.1%

   Participation in the Canaccord Genuity 2026 Musculoskeletal Conference with webcast access.

5. Feb 12

   Earnings date notice

   24h Move

   -4.8%

   Scheduling of Q4 and full-year 2025 results release and investor call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fda 510(k) clearance, arthroplasty, humeral stem

3 terms

fda 510(k) clearance regulatory

"follows a successful limited market release and receipt of additional FDA 510(k) clearance"

FDA 510(k) clearance is an official approval from the U.S. Food and Drug Administration that allows medical devices to be legally sold in the United States. It indicates the device is considered safe and effective based on its similarity to already approved products. For investors, achieving 510(k) clearance can signal a company's readiness to bring a medical device to market and generate revenue.

arthroplasty medical

"be utilized in all primary, revision, and fracture total shoulder arthroplasty procedures"

Arthroplasty is a surgical procedure that replaces or repairs a damaged joint — commonly the hip or knee — by fitting an artificial joint or resurfacing the joint surface, much like replacing a worn hinge on a door so it moves smoothly again. Investors care because the procedure drives demand for medical devices, hospital services, implants, and follow-up care; trends in procedure volume, technology improvements, reimbursement rates, and aging populations can directly affect revenues and costs across healthcare companies and insurers.

humeral stem medical

"full commercial launch of the InSet™ I-135RFX Humeral Stem"

A humeral stem is the metal or composite rod implanted into the upper arm bone as the anchored part of a shoulder replacement, serving like the handle that connects an artificial joint to the skeleton. Investors care because its design, materials and fixation method drive product durability, surgical complexity and revision rates, which in turn affect device demand, pricing, warranty costs and regulatory scrutiny.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Latest Addition to I-Series Product Line Follows a Successful Limited Market Release and FDA
Clearance of Additional Fracture Indications

GRAND RAPIDS, Mich., April 27, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the Company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced full commercial launch of the InSet™ I-135RFX Humeral Stem ("InSet™ I-135RFX").

The commencement of full launch follows a successful limited market release and receipt of additional FDA 510(k) clearance for an expanded set of fracture indications, enabling the InSet™ I-135RFX to now be utilized in all primary, revision, and fracture total shoulder arthroplasty procedures.

"The addition of the InSet I-135RFX to our best-in-class suite of shoulder surgical care solutions is an important milestone for SI, enabling us to now support the full spectrum of shoulder arthroplasty procedures our surgeon customers perform," said Rob Ball, CEO of Shoulder Innovations. "As the third addition to our InSet Humeral Stem System in as many years, this launch reflects the strength of our innovation engine and our commitment to delivering meaningful improvements in patient outcomes, even in the most challenging of clinical scenarios."

The InSet™ I-135RFX joins the smaller form factor InSet™ 95 and InSet™ 70, launched in 2024 and 2025, respectively, as the third addition to the I-Series humeral stem product line. Consistent with these earlier products, the InSet™ I-135RFX is built on Shoulder Innovations' exclusive InSet lateral-lateral implant philosophy, which has been shown in independent, peer reviewed research to reduce complications and maximize post-operative range of motion.

To date, surgeons have utilized the InSet™ I-135RFX in both anatomic and reverse shoulder arthroplasty configurations and specifically value its ease of use, straightforward surgical technique, and seamless integration with Shoulder Innovations' two-tray surgical instrumentation system.

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact 
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-initiates-full-commercial-launch-of-the-inset-i-135rfx-humeral-stem-302753843.html

SOURCE Shoulder Innovations

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Shoulder Innovations' April 27, 2026 launch of the InSet I-135RFX (SI) mean for surgeons?

The InSet I-135RFX is now commercially available for a full range of shoulder arthroplasty procedures. According to Shoulder Innovations, it follows limited release and expanded FDA 510(k) fracture clearance and integrates with the company’s two-tray surgical instrumentation system.

Does the InSet I-135RFX (SI) have FDA clearance for fracture indications?

Yes. The InSet I-135RFX received additional FDA 510(k) clearance for expanded fracture indications. According to Shoulder Innovations, that clearance enables use in primary, revision, and fracture total shoulder arthroplasty procedures.

How does the InSet I-135RFX (SI) relate to previous InSet humeral stems?

The I-135RFX is the third InSet humeral stem added over three years to the I-Series. According to Shoulder Innovations, it complements the InSet 95 and InSet 70 and shares the same lateral-lateral implant philosophy.

What clinical benefits are associated with the InSet lateral-lateral philosophy used in the I-135RFX (SI)?

Independent peer-reviewed research has shown the InSet lateral-lateral approach can reduce complications and maximize post-operative range of motion. According to Shoulder Innovations, the I-135RFX is built on that philosophy.

Can the InSet I-135RFX (SI) be used in both anatomic and reverse shoulder arthroplasty?

Yes. Surgeons have used the I-135RFX in both anatomic and reverse configurations. According to Shoulder Innovations, clinicians value its straightforward surgical technique and seamless fit with the two-tray instrumentation system.